ClinicalTrials.gg
RecruitingNCT06479135POIESISUpdated Sep 25, 2025

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

A Phase 3 interventional study of Navtemadlin and Navtemadlin placebo in Myelofibrosis, Post-PV MF and Post-ET Myelofibrosis, sponsored by Kartos Therapeutics, Inc.. Recruiting at 215 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Kartos Therapeutics, Inc. (part of Ipsen) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 453 studies in Primary Myelofibrosis with a site in United States — 69 open to participants now, 104 under way, 12 of them phase 3. Primary Myelofibrosis · United States.

Planned enrollment
3rd of 387
600 · median 40
Started
2024
with 15 others
Phase 3
42 of 453
4 open now
Primary completion
2026-12
later than 28 of 103 live
Registered
422nd of 453
by date

Among the 453 studies in Primary Myelofibrosis with a site in United States, this one is the 3rd largest by planned enrollment of the 387 interventional ones that give a count, is one of 16 that started in 2024, is one of 42 in phase 3, reaches primary completion later than 28 of the 103 other live ones, and was the 422nd registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

69 of the 453 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:

64 more — sign in →

All 69 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 453 studies in Primary Myelofibrosis with a site in United States, or all of them as a file.
02

Study summary

This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.

Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxolitinib. Randomized means that subjects will be assigned to a group by chance, like a flip of a coin. The study is blinded, meaning the subjects, doctors, central endpoint assessors and sponsor will not know which add on treatment (navtemadlin or navtemadlin placebo) the subject is receiving.

03

Conditions studied

  • Myelofibrosis
  • Post-PV MF
  • Post-ET Myelofibrosis
  • Primary Myelofibrosis
  • MF

Browse trials for

Keywords

  • Navtemadlin
  • KRT-232
  • Ruxolitinib
  • POIESIS
  • TP53
  • Suboptimal response
  • Sub-optimal response
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Ruxolitinib Alone Period:

  • Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by the treating physician according to the World Health Organization (WHO) criteria
  • High, Intermediate-1, Intermediate-2 risk category International Prognosis System Score (IPSS)
  • (ECOG) performance status of 0 to 2
  • JAK-inhibitor treatment naive

Exclusion Criteria for Ruxolitinib Alone Period:

  • Prior Splenectomy
  • Splenic irradiation within 3 months prior to the first dose
  • Prior BCL-XL, BET, MDM2, PI3K, PIM, or XPO1 inhibitors therapy or p53-directed therapy
  • Eligible for Bone Marrow Transplant
  • Peripheral blood or bone marrow blast count ≥ 10 percent

Inclusion Criteria for Randomized Period:

  • PMF, post-PV MF, or post-ET MF that is TP53WT as assessed by central testing
  • ECOG performance status of 0 to 2
  • Treatment with a stable dose of ruxolitinib
  • Suboptimal response to run-in ruxolitinib treatment

Exclusion Criteria for Randomized Period:

  • Elevated white blood cell count that doubles (or more) during ruxolitinib treatment and exceeds 50 × 10\^9/L
  • Peripheral blood or bone marrow blast count ≥ 10 percent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Navtemadlin administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.

    Drug: Navtemadlin · Drug: Ruxolitinib

  • Active comparator
    Arm 2

    Navtemadlin placebo administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.

    Drug: Navtemadlin placebo · Drug: Ruxolitinib

Interventions

  • Navtemadlin is an investigational MDM2 inhibitor

    Also known as: KRT-232

  • DrugNavtemadlin placebo

    Navtemadlin placebo

    Also known as: KRT-232

  • Ruxolitinib is a janus kinase 1/2 inhibitor

    Also known as: Jakafi, Jakavi

06

What researchers measure

Primary outcomes

  1. To compare spleen volume reduction (SVR35) between Arm 1 and Arm 2

    The proportion of subjects in each arm with SVR35 by MRI/CT scan (central review) 24 weeks after start of the randomized period

    Time frame: 24 weeks

  2. To compare total symptom score reduction (TSS50) between Arm 1 and Arm 2

    The proportion of subjects in each arm with a TSS50 by the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 24 weeks after start of the randomized period

    Time frame: 24 weeks

Secondary outcomes

  1. To compare time to progression between Arm 1 and Arm 2

    Time to progression or death from any cause in subjects randomized to each arm

    Time frame: Up to 8 years

  2. To compare overall survival (OS) between Arm 1 and Arm 2

    Time to death from any cause in subjects randomized to each arm

    Time frame: Up to 8 years

07

Study locations

214 of 215 sites recruiting

Showing the first 100 of 215 sites across 19 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 22 phase 3 interventional studies under Primary Myelofibrosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 68. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2024
First posted
Jun 28, 2024
StartActual
Jun 3, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06479135
Responsible party
Sponsor
First posted
Jun 28, 2024
Start date
Jun 3, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 25, 2025

Study contacts

John Mei
Contact
jmei@kartosthera.com
650-542-0136

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navtemadlin

Start the discussion